Abstract
Immunosuppressant drugs like Etanercept, Mycophenolate mofetil, Sirolimus, Cyclosporine, and Rituximab can weaken the immune system and make patients susceptible to SARS nCoV-2 virus. These drugs make immunocompromised persons more vulnerable to complications associated with COVID-19. Moreover, it can also increase mortality and morbidity, as a weakened immune system can lead to a longer duration of infection. This study discusses the guidelines on immunosuppressant drugs and their associated risk factors with COVID-19, issued by the U.S CDC (Centers for Disease Control and Prevention), WHO (World Health Organization), U.S FDA (Food and Drug Administration), and other accredited global health organizations. Moreover, it also includes information about pharmaceutical properties, mechanism of action, COVID-19 associated risk factors, adverse drug reactions, contraindications, and drug-drug interactions. Our study will help government partners and international health organizations to understand COVID-19 health risks associated with immunosuppressants. Increased public awareness about effective drug therapy for autoimmune diseases, cancer treatment, immunocompromised, and organ transplant patients will help lower the mortality and morbidity associated with the disease amid the COVID-19 pandemic.
Keywords: COVID-19, immunosuppressant drugs, etanercept, mycophenolate mofetil, sirolimus, cyclosporine, rituximab.
Coronaviruses
Title:Immunosuppressant Drugs and Covid-19: Associated Risks, Drug-Drug Interactions and Contraindications
Volume: 2 Issue: 12
Author(s): Debjyoti Talukdar, Diane Ignacio and Madan Mohan Gupta*
Affiliation:
- School of Pharmacy, Faculty of Medical Sciences, The University of the West Indies, St. Augustine, Trinidad and Tobago,West Indies
Keywords: COVID-19, immunosuppressant drugs, etanercept, mycophenolate mofetil, sirolimus, cyclosporine, rituximab.
Abstract: Immunosuppressant drugs like Etanercept, Mycophenolate mofetil, Sirolimus, Cyclosporine, and Rituximab can weaken the immune system and make patients susceptible to SARS nCoV-2 virus. These drugs make immunocompromised persons more vulnerable to complications associated with COVID-19. Moreover, it can also increase mortality and morbidity, as a weakened immune system can lead to a longer duration of infection. This study discusses the guidelines on immunosuppressant drugs and their associated risk factors with COVID-19, issued by the U.S CDC (Centers for Disease Control and Prevention), WHO (World Health Organization), U.S FDA (Food and Drug Administration), and other accredited global health organizations. Moreover, it also includes information about pharmaceutical properties, mechanism of action, COVID-19 associated risk factors, adverse drug reactions, contraindications, and drug-drug interactions. Our study will help government partners and international health organizations to understand COVID-19 health risks associated with immunosuppressants. Increased public awareness about effective drug therapy for autoimmune diseases, cancer treatment, immunocompromised, and organ transplant patients will help lower the mortality and morbidity associated with the disease amid the COVID-19 pandemic.
Export Options
About this article
Cite this article as:
Talukdar Debjyoti, Ignacio Diane and Gupta Mohan Madan*, Immunosuppressant Drugs and Covid-19: Associated Risks, Drug-Drug Interactions and Contraindications, Coronaviruses 2021; 2 (12) : e070921193747 . https://dx.doi.org/10.2174/2666796702666210601125131
DOI https://dx.doi.org/10.2174/2666796702666210601125131 |
Print ISSN 2666-7967 |
Publisher Name Bentham Science Publisher |
Online ISSN 2666-7975 |
Call for Papers in Thematic Issues
Concurrent and Post COVID-19 Neuro-Ophthalmic Manifestations: Implications for Diagnosis and Treatment for Future Preparedness
COVID-19 typically presents with cough, fever, cough, and shortness of breath, with a wide range of clinical manifestations from asymptomatic to multiorgan failure and death. The infection is not just a respiratory disorder and can result in other clinical conditions. Neuro-ophthalmic presentations of COVID-19 (such as Headache and Ocular Pain, ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inherited Muscle Diseases Towards Improvements of the Mouse Model Catalogue
Current Genomics Tissue Engineering Techniques in Cardiac Repair and Disease Modelling
Current Pharmaceutical Design Chymase Inhibitors
Current Pharmaceutical Design Nanocarriers Assisted siRNA Gene Therapy for the Management of Cardiovascular Disorders
Current Pharmaceutical Design Erythropoietin and Oxidative Stress
Current Neurovascular Research Use of Chronic Disease Registries to Optimize Cardiovascular Health
Current Vascular Pharmacology Impact of Pulmonary Vascular Resistances in Heart Transplantation for Congenital Heart Disease
Current Cardiology Reviews Cutaneous Complications of Anderson-Fabry Disease
Current Pharmaceutical Design The Relationship Between HIV Infection and Cardiovascular Disease
Current Cardiology Reviews Mitochondria Damage in the Pathogenesis of Diabetic Retinopathy and in the Metabolic Memory Associated with its Continued Progression
Current Medicinal Chemistry Diabetes and Antioxidants: Myth or Reality?
Current Vascular Pharmacology Gene Therapy in Cardiovascular Diseases
Current Gene Therapy Signaling Epicenters: The Role of Caveolae and Caveolins in Volatile Anesthetic Induced Cardiac Protection
Current Pharmaceutical Design Evaluating Drug Safety in Children and Adolescents with Bipolar Disorder
Current Drug Safety Prediction of Degeneration of Native and Bioprosthetic Aortic Valves:Issue-Related Particularities of Diabetes Mellitus
Infectious Disorders - Drug Targets Supplementation of Creatine and Ribose Prevents Apoptosis and Right Ventricle Hypertrophy in Hypoxic Hearts
Current Pharmaceutical Design Adverse Effects of Cigarette Smoke and Induction of Oxidative Stress in Cardiomyocytes and Vascular Endothelium
Current Pharmaceutical Design Mitochondrial Dysfunction and Lipid Homeostasis
Current Drug Metabolism Future Perspectives in the Pharmacological Treatment of Atrial Fibrillation and Ventricular Arrhythmias in Heart Failure
Current Pharmaceutical Design Does A Subclinical Cardiotoxic Effect of Clozapine Exist? Results from a Follow-up Pilot Study
Cardiovascular & Hematological Agents in Medicinal Chemistry